SAB Biotherapeutics (SABS) Other Non Operating Income (2021 - 2026)
SAB Biotherapeutics (SABS) posted Other Non Operating Income of $626873.0 for Q1 2026, down 58.91% on a QoQ basis from $1.5 million in Q4 2025, and up 14.68% year-over-year from $546627.0 in Q1 2025.
SAB Biotherapeutics (SABS) Other Non Operating Income (2021 - 2026) Analysis & Trends
SAB Biotherapeutics' Other Non Operating Income history runs 6 years deep, the most recent figure standing at $626873.0 for Q1 2026.
- Quarterly Other Non Operating Income rose 14.68% year-over-year to $626873.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.2 million (up 27.33% YoY) and the FY2025 annual result came in at $3.1 million, up 27.77% from the prior year.
- Other Non Operating Income was $626873.0 for Q1 2026 at SAB Biotherapeutics, down from $1.5 million in the prior quarter.
- Across five years, Other Non Operating Income topped out at $7.8 million in Q1 2022 and bottomed at $1527.0 in Q3 2022.
- A 5-year average of $1.1 million and a median of $546627.0 in 2025 frame the typical range for Other Non Operating Income.
- Annual changes were most pronounced in 2022 — Other Non Operating Income sank 61.37% — and 2023, when it jumped 6264.31%.
- SAB Biotherapeutics' Other Non Operating Income stood at $32227.0 in 2022, then soared by 948.52% to $337906.0 in 2023, then surged by 153.03% to $854997.0 in 2024, then jumped by 78.44% to $1.5 million in 2025, then tumbled by 58.91% to $626873.0 in 2026.
- Business Quant data shows SABS's Other Non Operating Income at $626873.0 in Q1 2026, $1.5 million in Q4 2025, and $765881.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | SAB Biotherapeutics | 170.64 Mn | 170.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 626,873.00 |
| Dec 31, 2025 | 1.53 Mn |
| Sep 30, 2025 | 765,881.00 |
| Jun 30, 2025 | 295,630.00 |
| Mar 31, 2025 | 546,627.00 |
| Dec 31, 2024 | 854,997.00 |
| Sep 30, 2024 | 754,647.00 |
| Jun 30, 2024 | 367,832.00 |
| Mar 31, 2024 | 475,130.00 |
| Dec 31, 2023 | 337,906.00 |
| Sep 30, 2023 | 97,183.00 |
| Dec 31, 2022 | 32,227.00 |
| Sep 30, 2022 | 1,527.00 |
| Jun 30, 2022 | 1.67 Mn |
| Mar 31, 2022 | 7.79 Mn |
| Dec 31, 2021 | 1,535.00 |
| Sep 30, 2021 | 3,953.00 |
| Jun 30, 2021 | -69,138.00 |
| Mar 31, 2021 | 595,910.00 |